GTX-11 improves portal hypertension, liver fibrosis, and sinusoidal cells phenotype in experimental MASH
María Andrés‐Rozas, Jordi Gracia‐Sancho(University Hospital of Bern), Juan José Lozano(Instituto de Salud Carlos III), Zoe Boyer‐Díaz, Peio Aristu-Zabalza(Departament de Salut), Jaime Bosch(Instituto de Salud Carlos III), Jaume Mercadé(Highlight Therapeutics (Spain)), Sergi Guixé‐Muntet(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Carla Fuster(Hospital Clínic de Barcelona), Eugènia Ruiz-Cánovas(Highlight Therapeutics (Spain)), Cristina Fernández-Asensio(Highlight Therapeutics (Spain)), Noemı́ Garcı́a-Delgado(Highlight Therapeutics (Spain))
Cited by 2
Related Papers
Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease
|Journal of Hepatology|2020|163
Global burden of disease attributable to metabolic risk factors in adolescents and young adults aged 15–39, 1990–2021
|Clinical Nutrition|2024|44